Factor VIIa for correction of traumatic coagulopathy

Area of Science:

• Trauma and Emergency Medicine
• Hematology
• Pharmacology

Background:

• Activated factor VIIa (FVIIa) is a procoagulant agent initially developed for hemophilia treatment.
• Anecdotal evidence suggested FVIIa's utility in trauma-induced coagulopathy, but large-scale data were lacking.
• This study retrospectively analyzed FVIIa use in 81 coagulopathic trauma patients from 2001-2003.

Purpose of the Study:

• To evaluate the efficacy and outcomes of FVIIa in treating coagulopathy in trauma patients.
• To compare outcomes of FVIIa-treated patients with a matched cohort of coagulopathic trauma patients who did not receive FVIIa.

Main Methods:

• FVIIa administration was restricted to patients with active hemorrhage and clinical coagulopathy.
• Data collected included coagulopathy cause, FVIIa dose, coagulation parameters, blood product usage, length of stay, and patient outcomes.
• Outcomes were compared between FVIIa recipients and a matched control group from the trauma registry.

Main Results:

• Coagulopathy reversal occurred in 75% of FVIIa-treated patients, with a significant reduction in prothrombin time (PT).
• Overall survival to hospital discharge was 42%, with diverse causes of death including irreversible shock and TBI.
• FVIIa patients exhibited higher mortality compared to matched controls, except for a small, highly matched subgroup.

Conclusions:

• FVIIa therapy rapidly reduced coagulopathic hemorrhage and improved laboratory coagulation measures.
• FVIIa is a potential last-resort therapy for uncontrolled coagulopathic hemorrhage after surgical bleeding control.
• Prospective trials are crucial to determine optimal patient selection, dosage, and timing for FVIIa in traumatic coagulopathy.